CN102159209A - 听力缺失的治疗 - Google Patents

听力缺失的治疗 Download PDF

Info

Publication number
CN102159209A
CN102159209A CN2009801365537A CN200980136553A CN102159209A CN 102159209 A CN102159209 A CN 102159209A CN 2009801365537 A CN2009801365537 A CN 2009801365537A CN 200980136553 A CN200980136553 A CN 200980136553A CN 102159209 A CN102159209 A CN 102159209A
Authority
CN
China
Prior art keywords
receptor agonist
adenosine receptor
noise
adenosine
adac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801365537A
Other languages
English (en)
Chinese (zh)
Inventor
S·维拉杰科维克
P·R·索恩
G·D·豪斯利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Original Assignee
Auckland Uniservices Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd filed Critical Auckland Uniservices Ltd
Publication of CN102159209A publication Critical patent/CN102159209A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801365537A 2008-08-11 2009-08-11 听力缺失的治疗 Pending CN102159209A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ57046908 2008-08-11
NZ570469 2008-08-11
PCT/NZ2009/000164 WO2010019057A1 (en) 2008-08-11 2009-08-11 The treatment of hearing loss

Publications (1)

Publication Number Publication Date
CN102159209A true CN102159209A (zh) 2011-08-17

Family

ID=41669060

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801365537A Pending CN102159209A (zh) 2008-08-11 2009-08-11 听力缺失的治疗

Country Status (8)

Country Link
US (1) US20110207689A1 (enExample)
EP (1) EP2328577A4 (enExample)
JP (1) JP2011530585A (enExample)
CN (1) CN102159209A (enExample)
AU (1) AU2009280369A1 (enExample)
CA (1) CA2733918A1 (enExample)
MX (1) MX2011001551A (enExample)
WO (1) WO2010019057A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6279496B2 (ja) * 2015-01-08 2018-02-14 積水化成品工業株式会社 発泡粒子及び発泡成形体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248770A (en) * 1984-10-26 1993-09-28 The United States Of America, As Represented By The Department Of Health And Human Services Molecular probes for adenosine receptors
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
SE9401499D0 (sv) * 1994-05-02 1994-05-02 Item Dev Ab New method of treatment
AU2603197A (en) * 1996-04-10 1997-10-29 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Use of an a1 adenosine receptor agonist to treat cerebral ischaemia
US6649621B2 (en) * 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
WO2004096256A1 (en) * 2001-01-23 2004-11-11 The United States Of America, As Represented By The Secretary Of The Navy Methods for preventing and treating loss of balance function due to oxidative stress
EP2278999B1 (en) * 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions

Also Published As

Publication number Publication date
CA2733918A1 (en) 2010-02-18
JP2011530585A (ja) 2011-12-22
US20110207689A1 (en) 2011-08-25
EP2328577A4 (en) 2011-10-19
MX2011001551A (es) 2011-03-29
AU2009280369A1 (en) 2010-02-18
WO2010019057A1 (en) 2010-02-18
EP2328577A1 (en) 2011-06-08

Similar Documents

Publication Publication Date Title
US9889107B2 (en) Methods and compositions for preventing and treating auditory dysfunctions
Himeno et al. Intra-cochlear administration of dexamethasone attenuates aminoglycoside ototoxicity in the guinea pig
Takemura et al. Direct inner ear infusion of dexamethasone attenuates noise-induced trauma in guinea pig
US6649621B2 (en) Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US8507525B2 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
Shoji et al. Differential protective effects of neurotrophins in the attenuation of noise-induced hair cell loss
Pourbakht et al. Ebselen attenuates cochlear damage caused by acoustic trauma
KR101429735B1 (ko) 와우각 흥분독성에 의해 유발된 이명의 치료를 위한 ｎｍｄａ 수용체 길항제의 용도
US10966940B2 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
CN110337291A (zh) 治疗耳蜗突触病变的方法
Wong et al. Post exposure administration of A1 adenosine receptor agonists attenuates noise-induced hearing loss
Niu et al. The signal transduction pathway for the dopamine D1 receptor in the guinea-pig cochlea
Bielefeld Protection from noise-induced hearing loss with Src inhibitors
CN102159209A (zh) 听力缺失的治疗
US20210253689A1 (en) REGIMENS, COMPOSITIONS AND METHODS WITH CAPSAICIN AND TNF-alpha INHIBITOR
Öntepeli et al. Audiometry results and TEOAE and DPOAE amplitudes in men taking a phosphodiesterase type 5 inhibitor for erectile dysfunction
US20240294925A1 (en) Method of Treatment for Auditory Dysfunction
KR20150083167A (ko) 메틸렌 블루를 포함하는 감각신경성 난청의 치료 또는 예방용 약학 조성물
EP4501346A1 (en) Method for the prevention of hearing loss induced by a platinum-based chemotherapy drug
Tan Characterisation of Noise-Induced Cochlear Inflammation
Escabi et al. Noise-Induced Hearing Loss and Drug Therapy: Basic and Translational Science
INTRATYMPANIC Intratympanic Pharmacotherapy
Perez et al. Local drug delivery for inner ear therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110817